Inhibitor of the tyrosine phosphatase step reverses cognitive deficits in a mouse model of alzheimer’s disease

PLoS Biology

Volumn 12, Issue 8, 2014, Pages

  Xu, Jian ^a   Chatterjee, Manavi ^a   Baguley, Tyler D ^b   Brouillette, Jonathan ^a   Kurup, Pradeep ^a   Ghosh, Debolina ^a   Kanyo, Jean ^b   Zhang, Yang ^a,c   Seyb, Kathleen ^c   Ononenyi, Chimezie ^a   Foscue, Ethan ^a   Anderson, George M ^a,d   Gresack, Jodi ^e   Cuny, Gregory D ^c   Glicksman, Marcie A ^c   Greengard, Paul ^e   Lam, Tukiet T ^b   Tautz, Lutz ^f   Nairn, Angus C ^d   Ellman, Jonathan A ^b   Lombroso, Paul J ^a,d   more..

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e ROCKEFELLER UNIVERSITY   (United States)

^f BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; BENZOPENTATHIEPIN 8 (TRIFLUOROMETHYL) 1,2,3,4,5 BENZOPENTATHIEPIN 6 AMINE; FOCAL ADHESION KINASE 2; GLUTAMATE RECEPTOR; GLUTAMATE RECEPTOR GLUN2B; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; STRIATAL ENRICHED PROTEIN TYROSINE PHOSPHATASE; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG MECHANISM; EMBRYO; ENZYME INHIBITION; ENZYME SUBSTRATE; IN VITRO STUDY; IN VIVO STUDY; LONGITUDINAL STUDY; MALE; MOUSE; NONHUMAN; PHARMACOPHORE; PROTEIN PHOSPHORYLATION; RAT;

MUS;

EID: 84935900032     PISSN: 15449173     EISSN: 15457885     Source Type: Journal    
DOI: 10.1371/journal.pbio.1001923     Document Type: Article

References (62)

1. Lombroso PJ, Murdoch G, Lerner M (1991) Molecular characterization of a protein-tyrosine-phosphatase enriched in striatum. Proc Natl Acad Sci U S A 88: 7242-7246.
2. Lombroso PJ, Naegele JR, Sharma E, Lerner M (1993) A protein tyrosine phosphatase expressed within dopaminoceptive neurons of the basal ganglia and related structures. J Neurosci 13: 3064-3074.
3. Boulanger LM, Lombroso PJ, Raghunathan A, During MJ, Wahle P, et al. (1995) Cellular and molecular characterization of a brain-enriched protein tyrosine phosphatase. J Neurosci 15: 1532-1544.
4. Oyama T, Goto S, Nishi T, Sato K, Yamada K, et al. (1995) Immunocytochemical localization of the striatal enriched protein tyrosine phosphatase in the rat striatum: a light and electron microscopic study with a complementary DNAgenerated polyclonal antibody. Neuroscience 69: 869-880.
5. Chin J, Palop JJ, Puolivali J, Massaro C, Bien-Ly N, et al. (2005) Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease. J Neurosci 25: 9694-9703.
6. Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, et al. (2005) Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci 8: 1051-1058.
7. Kurup P, Zhang Y, Xu J, Venkitaramani DV, Haroutunian V, et al. (2010) A beta-mediated NMDA receptor endocytosis in Alzheimer's disease involves ubiquitination of the tyrosine phosphatase STEP61. J Neurosci 30: 5948-5957.
8. Carty NC, Xu J, Kurup P, Brouillette J, Goebel-Goody SM, et al. (2012) The tyrosine phosphatase STEP: implications in schizophrenia and the molecular mechanism underlying antipsychotic medications. Transl Psychiatry 2: e137.
9. Goebel-Goody SM, Wilson-Wallis ED, Royston S, Tagliatela SM, Naegele JR, et al. (2012) Genetic manipulation of STEP reverses behavioral abnormalities in a fragile X syndrome mouse model. Genes Brain Behav 11: 586-600.
10. Goebel-Goody SM, Baum M, Paspalas CD, Fernandez SM, Carty NC, et al. (2012) Therapeutic implications for striatal-enriched protein tyrosine phosphatase (STEP) in neuropsychiatric disorders. Pharmacol Rev 64: 65-87.
11. Munoz JJ, Tarrega C, Blanco-Aparicio C, Pulido R (2003) Differential interaction of the tyrosine phosphatases PTP-SL, STEP and HePTP with the mitogen-activated protein kinases ERK1/2 and p38alpha is determined by a kinase specificity sequence and influenced by reducing agents. Biochem J 372: 193-201.
12. Paul S, Nairn AC, Wang P, Lombroso PJ (2003) NMDA-mediated activation of the tyrosine phosphatase STEP regulates the duration of ERK signaling. Nat Neurosci 6: 34-42.
13. Nguyen TH, Liu J, Lombroso PJ (2002) Striatal enriched phosphatase 61 dephosphorylates Fyn at phosphotyrosine 420. J Biol Chem 277: 24274-24279.
14. Xu J, Kurup P, Bartos JA, Patriarchi T, Hell JW, et al. (2012) Striatal-enriched protein-tyrosine phosphatase (STEP) regulates Pyk2 kinase activity. J Biol Chem 287: 20942-20956.
15. Xu J, Kurup P, Zhang Y, Goebel-Goody SM, Wu PH, et al. (2009) Extrasynaptic NMDA receptors couple preferentially to excitotoxicity via calpain-mediated cleavage of STEP. J Neurosci 29: 9330-9343.
16. Zhang Y, Kurup P, Xu J, Carty N, Fernandez SM, et al. (2010) Genetic reduction of striatal-enriched tyrosine phosphatase (STEP) reverses cognitive and cellular deficits in an Alzheimer's disease mouse model. Proc Natl Acad Sci U S A 107: 19014-19019.
17. Moult PR, Gladding CM, Sanderson TM, Fitzjohn SM, Bashir ZI, et al. (2006) Tyrosine phosphatases regulate AMPA receptor trafficking during metabotropic glutamate receptor-mediated long-term depression. J Neurosci 26: 2544-2554.
18. Zhang Y, Venkitaramani DV, Gladding CM, Kurup P, Molnar E, et al. (2008) The tyrosine phosphatase STEP mediates AMPA receptor endocytosis after metabotropic glutamate receptor stimulation. J Neurosci 28: 10561-10566.
19. Davidson BS, Molinski TF, Barrows LR, Ireland CM (1991) Varacin: a novel benzopentathiepin from Lissoclinum vareau that is cytotoxic toward a human colon tumor. J Am Chem Soc 113: 4709-4710.
20. Kulikov AV, Tikhonova MA, Kulikova EA, Volcho KP, Khomenko TM, et al. (2012) A new synthetic varacin analogue, 8-(trifluoromethyl)-1,2,3,4,5-benzopentathiepin-6-amine hydrochloride (TC-2153), decreased hereditary catalepsy and increased the BDNF gene expression in the hippocampus in mice. Psychopharmacology (Berl) 221: 469-478.
21. Kulikov AV, Tikhonova MA, Kulikova EA, Khomenko TM, Korchagina DV, et al. (2011) [Effect of new potential psychotropic drug, 8-(trifluoromethyl)-1,2,3,4,5-benzopentathiepin-6-amine hydrochloride, on the expression of serotonin-related genes in mouse brain]. Mol Biol (Mosk) 45: 282-288.
22. Konstantinova LS, Rakitin OA, Rees CW (2004) Pentathiepins. Chem Rev 104: 2617-2630.
23. Khomenko TM, Tolstikova TG, Bolkunov AV, Dolgikh MP, Pavlova AV, et al. (2009) 8-(Trifluoromethyl)-1,2,3,4,5-benzopentathiepin-6-amine: novel aminobenzopentathiepine having in vivo anticonvulsant and anxiolytic activities. Letters in Drug Design & Discovery 6: 4.
24. Sergienko E, Xu J, Liu WH, Dahl R, Critton DA, et al. (2012) Inhibition of hematopoietic protein tyrosine phosphatase augments and prolongs ERK1/2 and p38 activation. ACS Chem Biol 7: 367-377.
25. Vang T, Liu WH, Delacroix L, Wu S, Vasile S, et al. (2012) LYP inhibits T-cell activation when dissociated from CSK. Nat Chem Biol 8: 437-446.
26. Weibrecht I, Bohmer SA, Dagnell M, Kappert K, Ostman A, et al. (2007) Oxidation sensitivity of the catalytic cysteine of the protein-tyrosine phosphatases SHP-1 and SHP-2. Free Radical Biology & Medicine 43: 100-110.
27. Groen A, Lemeer S, van der Wijk T, Overvoorde J, Heck AJ, et al. (2005) Differential oxidation of protein-tyrosine phosphatases. J Biol Chem 280: 10298-10304.
28. Venkitaramani DV, Paul S, Zhang Y, Kurup P, Ding L, et al. (2009) Knockout of striatal enriched protein tyrosine phosphatase in mice results in increased ERK1/2 phosphorylation. Synapse 63: 69-81.
29. Bieth JG (1995) Theoretical and practical aspects of proteinase inhibition kinetics. Methods Enzymol 248: 59-84.
30. Eswaran J, von Kries JP, Marsden B, Longman E, Debreczeni JE, et al. (2006) Crystal structures and inhibitor identification for PTPN5, PTPRR and PTPN7: a family of human MAPK-specific protein tyrosine phosphatases. Biochem J 395: 483-491.
31. Kurup P, Xu J, Ononenyi C, Nairn AC, Lombroso PJ (2012) Role of STriatal-Enriched protein tyrosine Phosphatase (STEP) in Parkinson's disease (PD). New Orleans, LA: Society for Neuroscience.
32. Yang CH, Huang CC, Hsu KS (2012) A critical role for protein tyrosine phosphatase nonreceptor type 5 in determining individual susceptibility to develop stress-related cognitive and morphological changes. J Neurosci 32: 7550-7562.
33. Dabrowska J, Hazra R, Guo JD, Li C, Dewitt S, et al. (2013) Striatal-enriched protein tyrosine phosphatase-STEPs toward understanding chronic stressinduced activation of corticotrophin releasing factor neurons in the rat bed nucleus of the stria terminalis. Biol Psychiatry 74: 817-826.
34. Darcq E, Hamida SB, Wu S, Phamluong K, Kharazia V, et al. (2014) Inhibition of striatal-enriched tyrosine phosphatase 61 in the dorsomedial striatum is sufficient to increased ethanol consumption. J Neurochem: 129(6):1024-34.
35. Deb I, Manhas N, Poddar R, Rajagopal S, Allan AM, et al. (2013) Neuroprotective role of a brain-enriched tyrosine phosphatase, STEP, in focal cerebral ischemia. J Neurosci 33: 17814-17826.
36. Briggs SW, Walker J, Asik K, Lombroso P, Naegele J, et al. (2011) STEP regulation of seizure thresholds in the hippocampus. Epilepsia 52: 497-506.
37. Hicklin TR, Wu PH, Radcliffe RA, Freund RK, Goebel-Goody SM, et al. (2011) Alcohol inhibition of the NMDA receptor function, long-term potentiation, and fear learning requires striatal-enriched protein tyrosine phosphatase. Proc Natl Acad Sci U S A 108: 6650-6655.
38. Tashev R, Moura PJ, Venkitaramani DV, Prosperetti C, Centonze D, et al. (2009) A substrate trapping mutant form of striatal-enriched protein tyrosine phosphatase prevents amphetamine-induced stereotypies and long-term potentiation in the striatum. Biol Psychiatry 65: 637-645.
39. Saavedra A, Giralt A, Rue L, Xifro X, Xu J, et al. (2011) Striatal-enriched protein tyrosine phosphatase expression and activity in Huntington's disease: a STEP in the resistance to excitotoxicity. J Neurosci 31: 8150-8162.
40. Gladding CM, Sepers MD, Xu J, Zhang LY, Milnerwood AJ, et al. (2012) Calpain and STriatal-Enriched protein tyrosine phosphatase (STEP) activation contribute to extrasynaptic NMDA receptor localization in a Huntington's disease mouse model. Hum Mol Genet 21: 3739-3752.
41. Valjent E, Pascoli V, Svenningsson P, Paul S, Enslen H, et al. (2005) Regulation of a protein phosphatase cascade allows convergent dopamine and glutamate signals to activate ERK in the striatum. Proc Natl Acad Sci U S A 102: 491-496.
42. Almeida CG, Takahashi RH, Gouras GK (2006) Beta-amyloid accumulation impairs multivesicular body sorting by inhibiting the ubiquitin-proteasome system. J Neurosci 26: 4277-4288.
43. Tseng BP, Green KN, Chan JL, Blurton-Jones M, LaFerla FM (2008) Abeta inhibits the proteasome and enhances amyloid and tau accumulation. Neurobiol Aging 29: 1607-1618.
44. Tautz L, Mustelin T (2007) Strategies for developing protein tyrosine phosphatase inhibitors. Methods 42: 250-260.
45. Lund IK, Andersen HS, Iversen LF, Olsen OH, Moller KB, et al. (2004) Structure-based design of selective and potent inhibitors of protein-tyrosine phosphatase beta. J Biol Chem 279: 24226-24235.
46. Zhang S, Liu S, Tao R, Wei D, Chen L, et al. (2012) A highly selective and potent PTP-MEG2 inhibitor with therapeutic potential for type 2 diabetes. J Am Chem Soc 134: 18116-18124.
47. Boivin B, Yang M, Tonks NK (2010) Targeting the reversibly oxidized protein tyrosine phosphatase superfamily. Sci Signal 3: p12.
48. den Hertog J, Ostman A, Bohmer FD (2008) Protein tyrosine phosphatases: regulatory mechanisms. The FEBS J 275: 831-847.
49. Ostman A, Frijhoff J, Sandin A, Bohmer FD (2011) Regulation of protein tyrosine phosphatases by reversible oxidation. J Biochem 150: 345-356.
50. Winterbourn CC, Hampton MB (2008) Thiol chemistry and specificity in redox signaling. Free Radical Biology & Medicine 45: 549-561.
51. Meng TC, Fukada T, Tonks NK (2002) Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo. Mol Cell 9: 387-399.
52. Woo HA, Yim SH, Shin DH, Kang D, Yu DY, et al. (2010) Inactivation of peroxiredoxin I by phosphorylation allows localized H(2)O(2) accumulation for cell signaling. Cell 140: 517-528.
53. Krishnan N, Fu C, Pappin DJ, Tonks NK (2011) H2S-induced sulfhydration of the phosphatase PTP1B and its role in the endoplasmic reticulum stress response. Sci Signal 4: ra86.
54. Chen YY, Chu HM, Pan KT, Teng CH, Wang DL, et al. (2008) Cysteine Snitrosylation protects protein-tyrosine phosphatase 1B against oxidation-induced permanent inactivation. J Biol Chem 283: 35265-35272.
55. Tonks NK (2005) Redox redux: revisiting PTPs and the control of cell signaling. Cell 121: 667-670.
56. Venkitaramani DV, Chin J, Netzer WJ, Gouras GK, Lesne S, et al. (2007) Betaamyloid modulation of synaptic transmission and plasticity. J Neurosci 27: 11832-11837.
57. Zanke B, Squire J, Griesser H, Henry M, Suzuki H, et al. (1994) A hematopoietic protein tyrosine phosphatase (HePTP) gene that is amplified and overexpressed in myeloid malignancies maps to chromosome 1q32.1. Leukemia 8: 236-244.
58. Hendriks W, Schepens J, Brugman C, Zeeuwen P, Wieringa B (1995) A novel receptor-type protein tyrosine phosphatase with a single catalytic domain is specifically expressed in mouse brain. Biochem J 305 (Pt 2): 499-504.
59. Ogata M, Sawada M, Fujino Y, Hamaoka T (1995) cDNA cloning and characterization of a novel receptor-type protein tyrosine phosphatase expressed predominantly in the brain. J Biol Chem 270: 2337-2343.
60. Sharma E, Lombroso PJ (1995) A neuronal protein tyrosine phosphatase induced by nerve growth factor. J Biol Chem 270: 49-53.
61. Brouillette J, Quirion R (2008) Transthyretin: a key gene involved in the maintenance of memory capacities during aging. Neurobiol Aging 29: 1721-1732.
62. Bult A, Zhao F, Dirkx R, Jr., Sharma E, Lukacsi E, et al. (1996) STEP61: a member of a family of brain-enriched PTPs is localized to the endoplasmic reticulum. J Neurosci 16: 7821-7831.